Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 2
2008 2
2009 1
2010 2
2011 2
2012 4
2013 3
2014 3
2015 2
2016 2
2017 1
2018 2
2019 4
2020 3
2021 3
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

38 results
Results by year
Filters applied: . Clear all
Page 1
Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway.
Alicea-Torres K, Sanseviero E, Gui J, Chen J, Veglia F, Yu Q, Donthireddy L, Kossenkov A, Lin C, Fu S, Mulligan C, Nam B, Masters G, Denstman F, Bennett J, Hockstein N, Rynda-Apple A, Nefedova Y, Fuchs SY, Gabrilovich DI. Alicea-Torres K, et al. Nat Commun. 2021 Mar 19;12(1):1717. doi: 10.1038/s41467-021-22033-2. Nat Commun. 2021. PMID: 33741967 Free PMC article.
[Complex treatment of a patient with neurofibromatosis type 2].
Rynda AY, Olyushin VE, Rostovtsev DM, Zabrodskaya YM. Rynda AY, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(8):98-104. doi: 10.17116/jnevro202012008198. Zh Nevrol Psikhiatr Im S S Korsakova. 2020. PMID: 32929931 Russian.
Tolerance in the absence of autoantigen.
Pascual DW, Ochoa-Repáraz J, Rynda A, Yang X. Pascual DW, et al. Among authors: rynda a. Endocr Metab Immune Disord Drug Targets. 2007 Sep;7(3):203-10. doi: 10.2174/187153007781662549. Endocr Metab Immune Disord Drug Targets. 2007. PMID: 17897047 Review.
38 results